Eisai Announces Partnership With Newbridge to Market Breast Cancer Treatment Halaven® (Eribulin) Across the Middle East

Eisai Announces Partnership WithEisai Announces Partnership With Newbridge to Market Breast Cancer Treatment Halaven® (Eribulin) Across the Middle East PR Newswire HATFIELD, England, November 18, 2013 ®Eisai announces today that Halaven (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and NewBridge Pharmaceuticals. Eribulin is indicated for the treatment of locally advanced or metastatic breast cancer, which has progressed after at least two chemotherapeutic regimens for advanced disease. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for these treatments. "Our partnership with NewBridge is another significant step forward in support of our mission to increase the availability of Halaven worldwide," said Toshitaka Asano, Vice President Market Development Business Unit EMEA. Breast cancer is one of the major causes of cancer-related death in women and has become the most common malignant disease in the Middle East [1](ME). Studies show breast cancer is the most common form among [2]women in Saudi Arabia, representing approximately 22% of all cancers. Locally advanced disease is very common in Saudi Arabia, Egypt, Tunisia and other ME countries. In the United Arab Emirates, 30% of women with breast cancer present in the third stage of the disease.